Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($1.58) per share and revenue of $145.98 million for the quarter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. On average, analysts expect Ultragenyx Pharmaceutical to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $38.07 on Wednesday. The stock has a market cap of $3.57 billion, a P/E ratio of -6.00 and a beta of 0.61. The firm has a 50 day moving average price of $37.66 and a 200 day moving average price of $43.42. Ultragenyx Pharmaceutical has a 52-week low of $29.59 and a 52-week high of $60.37.

Insider Activity

In related news, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at $2,116,156.50. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 124,643 shares of company stock worth $5,256,268 in the last quarter. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Canaccord Genuity Group raised their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Piper Sandler reduced their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research note on Monday, March 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.